

or the offices of the Board of Governors not later than April 27, 1985.

**A. Federal Reserve Bank of Atlanta** (Robert E. Heck, Vice President) 104 Marietta Street NW., Atlanta, Georgia 30303:

1. *Mansura Bancshares, Inc.*, Mansura, Louisiana; to engage *de novo* through its subsidiary, Cypress Data Processing Co., Mansura, Louisiana, in data processing activities in the State of Louisiana.

**B. Federal Reserve Bank of San Francisco** (Harry W. Green, Vice President) 101 Market Street, San Francisco, California 94105:

1. *North Valley Bancorp*, Redding, California; to engage *de novo* through its subsidiary North Valley Consulting Services, Redding, California, in providing management consulting services to depository institutions.

Board of Governors of the Federal Reserve System, April 1, 1985.

James McAfee,

*Associate Secretary of the Board.*

[FR Doc. 85-8162 Filed 4-4-85; 8:45 am]

BILLING CODE 6210-01-M

#### **Rainier National Bank; Corporation To Do Business Under Section 25(a) of the Federal Reserve Act**

An application has been submitted for the Board's approval of the organization of a corporation to do business under section 25(a) of the Federal Reserve Act ("Edge Corporation"). The Edge Corporation would operate as a subsidiary of the applicant. The factors that are to be considered in acting on the application are set forth in § 211.4(a) of the Board's Regulation K (12 CFR 211.4(a)).

The application may be inspected at the offices of the Board of Governors or at the Federal Reserve Bank listed for the notice. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identify specifically any questions of fact that are in dispute, and summarize the evidence that would be presented at a hearing. Any person wishing to comment on the application should submit views in writing to be received not later than April 29, 1985.

**A. Board of Governors of the Federal Reserve System**, (William W. Wiles, Secretary) Washington, D.C. 20551:

*Rainier National Bank*, Seattle, Washington; to establish a corporation to be known as Rainier Bank International, New York, New York. Rainier Bank International would operate as a subsidiary of Rainier National Bank. This application may be

inspected at the Federal Reserve Bank of San Francisco.

Board of Governors of the Federal Reserve System, April 1, 1985.

James McAfee,

*Associate Secretary of the Board.*

[FR Doc. 85-8163 Filed 4-4-85; 8:45 am]

BILLING CODE 6210-01-M

#### **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

##### **Office of the Secretary**

##### **Agency Forms Submitted to the Office of Management and Budget for Clearance**

Each Friday the Department of Health and Human Services (HHS) publishes a list of information collection packages it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). The following are those packages submitted to OMB since the last list was published on March 29, 1985.

##### **Public Health Services**

###### *Health Resources and Service Administration*

**Subject:** Collection of Information Under the Health Education Assistance Loan Program (HEAL)—Existing Collection  
**Respondents:** Individuals, businesses, non-profit institutions

###### *National Institutes of Health*

**Subject:** Individual National Research Service Award Application—Revision (0925-0002)

**Respondents:** Individuals  
**OMB Desk Officer:** Fay S. Iudicello

###### *Food and Drug Administration*

**Subject:** Product License Application the Manufacturing of Human T-Lymphotropic Virus for In-Vitro Diagnostic Use—new

**Respondents:** Businesses, small businesses, non-profit institutions  
**OMB Desk Officer:** Bruce Artim

###### *Health Care Financing Administration*

**Subject:** Recalculation of Case Mix Index Based on Total Medicare Discharges—HCFA 9043—Extension (0938-0312)

**Respondents:** State/local governments, businesses, or other for-profit, non-profit institutions

**Subject:** Statistical Report on Medical Care: (Eligibles, Recipients, Payments and Services) HCFA—2082—Extension (0938-0345)

**Respondents:** State/local governments, Medicaid agents

**Subject:** Preclearance: Design and Evaluation of the Home Health Agency Prospective Payment Demonstration—New

**Respondents:** Businesses, for-profit, non-profit institutions

**OMB Desk Officer:** Fay S. Iudicello

Copies of the above information collection clearance packages can be obtained by calling the HHS Reports Clearance Officer on 202-245-6511.

Written comments and recommendations for the proposed information collections should be sent directly to the appropriate OMB Desk Officer designated above at the following address: OMB Reports Management Branch, New Executive Office Building, Room 3208, Washington, D.C. 20503, ATTN: (name of OMB Desk Officer).

Dated: April 1, 1985.

Wallace O. Keene,

*Acting Deputy Assistant Secretary for Management Analysis and Systems.*

[FR Doc. 85-8203 Filed 4-4-85; 8:45 a.m.]

BILLING CODE 4150-04-M

#### **Alcohol, Drug Abuse, and Mental Health Administration**

##### **Rape Prevention and Control Advisory Committee; Meeting**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (5 U.S.C. Appendix I) announcement is made of the following national advisory body scheduled to assemble during the month of April 1985.

##### **Rape Prevention and Control Advisory Committee**

April 15-16; 9:00 a.m., Parklawn Building, Conference Rooms "O" and "H", 5600 Fishers Lane, Rockville, Maryland 20857

Open

Contact: Ann Maney, Ph.D., Executive Secretary, Rape Prevention and Control Advisory Committee, 5600 Fishers Lane, Room 6C-12, Rockville, Maryland 20857, (301) 443-1910

Purpose: The Rape Prevention and Control Advisory Committee advises the Secretary, Department of Health and Human Services, the Administrator, Alcohol, Drug Abuse, and Mental Health Administration, and the Director, National Institute of Mental Health through the National Center for the Prevention and Control of Rape (NCPCR), on matters regarding the needs and concerns associated with rape in the United States and makes recommendations pertaining to activities to be undertaken by the Department to address the problems of rape. Agenda: The entire meeting will be open to the public. It will include discussions of

emergency service training materials by NCPCC, the state-of-the-art in research in emergency services to rape victims, and strategies for dissemination of existing materials as well as for the development of future studies.

Substantive program information may be obtained from the contact person listed above. Summaries of the meetings and roster of Committee members may be obtained from Ms. Helen W. Garrett, Committee Management Officer, National Institute of Mental Health, Room 17C26, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, (301) 443-4333.

Dated: April 1, 1985.

Sue Simons,

Committee Management Officer, Alcohol, Drug Abuse, and Mental Health Administration.

[FR Doc. 85-8134 Filed 4-4-85; 8:45 am]

BILLING CODE 4160-20-M

## Food and Drug Administration

[Docket No. 85N-0139]

### Riker Laboratories, Inc., et al; Withdrawal of Approval of New Drug Applications

AGENCY: Food and Drug Administration.

ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) withdraws approval of 72 new drug applications (NDAs) based on the written request of the applicants.

**EFFECTIVE DATE:** May 6, 1985.

#### FOR FURTHER INFORMATION CONTACT:

Ron Lyles, Center for Drugs and Biologics, Product Information Coordination Staff (HFN-105), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4320.

**SUPPLEMENTARY INFORMATION:** The holders of the NDAs listed below have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the NDAs. The applicants have also, by their request, waived their opportunity for hearing.

NDA	Drug name	Applicant's name and address
16-A	Isophlin	Riker Laboratories, Inc., 270-3A 3M Center, St. Paul, MN 55144.
3-224	Neo-Hombreol (M) Tablets.	Organon, Inc., West Orange, NJ 07052.
4-508	Tedral Enteric Coated Tablets.	Parke-Davis, 201 Tabor Rd., Morris Plains, NJ 07950.
5-237	Glyserol Tablets.	Dorsey Laboratories, Division of Sandoz, Inc., Box 83288, Lincoln, NE 68501.
5-599	Dicumarol Capsules.	Eli Lilly Co., 307 East McCarty St., Indianapolis, IN 46285.

NDA	Drug name	Applicant's name and address	NDA	Drug name	Applicant's name and address
6-374	Glyriazan (Theophylline Sodium Glycinate) Tablets and Elixir.	Scherer Laboratories, Inc., 14335 Gillis Rd., Dallas, TX 75234.	10-766	Ultra Feminine Estrogenic Hormone Cream with Progesterone.	Helena Rubenstein, 55 Hartz Way, Secaucus, NJ 07094
6-432	Nordihydroguaiarolic Acid.	Abbott Laboratories, North Chicago, IL 60064.	10-789	Phenylpropranolamine HCl Sustained Release Capsules.	USV Laboratories, Inc.
6-544	Johnson's Baby Lotion with Hexachlorophene.	Johnson & Johnson, New Brunswick, NJ 08903.	10-801	Ferrous Fumarate Tablets.	Do.
6-726	CPH Protein Hydrolysate Injection.	Cutter Laboratories, Inc., Div. Miles Labs, Inc., 2200 Powell St., Emeryville, CA 94608.	11-020	Dartal Tablets.	Searle.
6-937	Gustamine Powder.	USV Laboratories, Inc., USV Pharmaceutical Corp., 1 Scarsdale Rd., Tuckahoe, NY 10707.	11-424	Uftandren Tablets.	Ciba-Geigy Corp.
7-018	Thenfadil HCl Tablets and Symphecol Syrup.	Sterling Drugs, Inc., 90 Park Ave., New York, NY 10016.	11-560	Candettes Cough Lozenges.	Pfizer Inc.
7-071	Kriptin Tablets.	Whitehall Laboratories, 685 Third Ave., New York, NY 10017.	11-561	Candettes Cough Syrup.	Do.
7-103	Alko-Hist Tablets and Pyrilamine Maleate Tablets.	American Pharm. Co., 245 Fourth St., Passaic, NJ 07055.	11-814	Disomer Syrup and Tablets.	Shering Corp.
7-111	Antihistamine Tablets.	Revall Corp., 3901 North Kingshighway Blvd., St. Louis, MO 63115.	11-874	Carbetapentane Citrate Tablets.	USV Laboratories, Inc.
7-150	Co-Salt.	USV Laboratories.	11-922	Carbetapentane Citrate Capsules.	Do.
7-336	Verloid Tablets.	Riker Laboratories, Inc.	12-207	Quadrin Tablets.	Norwich Eaton Pharm., Inc., P.O. Box 191, Norwich, NY 13815.
7-735	Turicum Gel.	A. H. Robins Co., 1211 Sherwood Ave., Richmond, VA 23220.	12-233	Micrin Mouthwash and Gargle.	Johnson & Johnson
8-091	Banthine Injection.	Searle, Division of G. D. Searle & Co., 4901 Searle Pkwy., Skokie, IL 60077.	12-459	Nactone Tablets.	McNeil Pharm.
8-135	Tryptar Powder for Inhalation.	Armour Pharm. Co., Box 511, Kankakee, IL 60901.	12-519	Corodyl Forte Capsules.	Bock Pharmacol. Co., 5435 Highland Park Dr., St. Louis, MO 63110.
8-500	Isoniazid Tablets.	American Pharm. Co.	13-303	Tetrate 80 Capsules.	Pasadena Research Laboratories, Inc., 2107 East Villa, Pasadena, CA 91107.
8-579	Vallesril Tablets.	Searle.	13-644	Asthmanefrin/Vaponefrin Automatic Aerosol Mist.	USV Laboratories, Inc.
8-700	Danilone Tablets.	Almay, Inc., Apex, NC 27502.	13-992	First Aid Spray (Formula No. 511).	Johnson & Johnson
8-955	Cistin Elixir.	McNeil Pharm., Spring House, PA 19477.	14-162	Naponefrin Automatic/Asthmanefrin Automatic Aerosol Mist.	USV Laboratories, Inc.
8-977	Self-O-Rinse Cream.	USV Laboratories, Inc.	14-766	Metraspray Aerosol.	Riker Laboratories, Inc.
9-159	Rauwolfia Serpentina Tablets.	Do.	15-844	Betalin 12 Tablets.	Eli Lilly & Co.
9-244	Cortisone Acetate Tablets.	USV Laboratories, Inc.	16-053	Betapred Tablets.	Schering Corp.
9-269	Brompheniramine Maleate Bulk.	Schering Corp., 60 Orange St., Bloomfield, NJ 07003.	16-064	Intersept Antiseptic Foam.	Johnson & Johnson
9-304	Ambodryl HCl Injection.	Parke-Davis.	16-066	Chemestrogen.	T.E. Watson Co., P.O. Box 3829, Sarasota, FL 33578.
9-573	Reserpine Alkaloid Tablets.	USV Laboratories, Inc.	16-531	Tybatran Capsules.	A.H. Robins Co.
9-587	Proteroverine A & B Maleate Tablets.	D.	16-865	Rose Bengal Sodium I 131 Injection.	Mallinckrodt, Inc., P.O. Box 5840, St. Louis, MO 63134.
9-661	Alkaran Tablets.	Ferndale Laboratories, Inc., 780 West Eight Mile Rd., Ferndale, MI 48220.	16-814	Nonisodrine Aerosol.	Abbott Laboratories.
9-675	Astrofer Injection.	Astra Pharmaceutical Products, Inc., 7 Neponset St., Worcester, MA 01606.	16-991	Aarane Capsules.	Fisons Corp., Two Preston Ct., Bedford, MA 01730.
9-694	Depo-ACTH Sterile Solution.	The Upjohn Co., Kalamazoo, MI 49001.	17-278	Sodium Iodide I 125 Solution.	Mallinckrodt, Inc.
9-726	Sertane Tablets.	Bell Pharmaceutical Corp., Box 1968, Greenville, SC 29602.	17-359	2% Sodium Chloride for Therapeutic Abortion.	Cutter Laboratories, Inc.
9-760	Cytellin Suspension.	Eli Lilly & Co.	17-846	Radio-iodinated (I 125) Human Serum Albumins.	Miles Laboratories, Inc., P.O. Box 40, Elkhart, IN 46515.
9-784	Toclase Tablets.	Pfizer, Inc., 235 East 42nd St., New York, NY 10017.	17-847	Radio-iodinated (I 131) Human Serum Albumins.	Do.
9-850	Reserpoil Elixir.	The Upjohn Co.			
9-872	Pyrilamine Maleate Sustained Release Capsules.	USV Laboratories, Inc.			
10-385	Neomycin Sulfate Capsules and Tablets.	USV Laboratories, Inc.			
10-579	Terpin Hydrate and Methorate Hydrobromide.	The Upjohn Co.			
10-759	Sintrum Tablets.	Ciba-Geigy Corp., Summit, NJ 07901.			

The agency has determined that, in accordance with 21 CFR 25.24(d)(2) (proposed in the Federal Register of December 11, 1979 (44 FR 71742)), this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Therefore, under the Federal Food, Drug, and Cosmetic Act (sec. 505(e), 76 Stat. 782 as amended (21 U.S.C. 355(e))), and under authority delegated to the Director of the Center for Drugs and Biologics (21 CFR 5.82), approval of the new drug applications listed above, and supplements thereto, is hereby withdrawn.

This order becomes effective on May 6, 1985.

Dated: March 28, 1985.

Paul Parkman,

*Acting Director, Center for Drugs and Biologics.*

[FR Doc. 85-8137 Filed 4-4-85; 8:45 am]

BILLING CODE 4160-01-M

### Health Resources and Services Administration

#### Advisory Committee; Maternal and Child Health Research Grants Review Committee; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), announcement is made of the following National Advisory body scheduled to meet during the month of June 1985:

Name: Maternal and Child Health Research Grants Review Committee.

Date and Time: June 12-14, 1985, 9:00 a.m.-5:00 p.m.

Place: Conference Room M, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857; open on June 12, 1985, 9:00 a.m. to 10:00 a.m.; closed for remainder of meeting.

Purpose: The Committee is charged with the review of all research grant applications in the program areas of maternal and child health administered by the Bureau of Health Care Delivery and Assistance.

Agenda: The open portion of the meeting will cover opening remarks by the Director, Division of Maternal and Child Health, who will also report on program issues, Congressional activities and other topics of interest to the field of maternal and child health. The meeting will be closed to the public on June 12, 1985, from 10:00 a.m. for the remainder of the meeting for the review of research grant applications. The closing is in accordance with the Provision set forth in section 552b(c)(6), Title 5 U.S. Code, and the Determination by the Administrator, Health Resources and Services Administration, pursuant of Pub. L. 92-463.

Anyone wishing to obtain a roster of members, minutes of meetings, or other relevant information should write to or contact Gontran Lamberty, Dr. P.H., Executive Secretary, Maternal and Child Health Research Grants Review Committee, Room 6-17, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, telephone: 301 443-2190.

Agenda items are subject to change as priorities dictate.

Dated: April 1, 1985.

Jackie E. Baum,

*Advisory Committee Management Officer, HRSA.*

[FR Doc. 85-8132 Filed 4-4-85; 8:45 am]

BILLING CODE 4160-15-M

#### Advisory Committee; Meeting; Task Force on Organ Transplantation

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), announcement is made of the following national advisory bodies scheduled to meet during the month of April 1985:

Name: Task Force on Organ Transplantation.

Date and Time: April 23, 1985 8:00 a.m.-4:00 p.m.

Place: Shoreham Hotel, 2500 Calvert Street and Connecticut Avenue NW., Washington, D.C. 20008; the entire meeting is open to the public.

Purpose: The Task Force on Organ Transplantation is required to conduct comprehensive examinations of the medical, legal, ethical economic, and social issues presented by human organ procurement and transplantation; including an assessment of immunosuppressive medications used to prevent organ rejection in transplant patients. Reports on these issues are required to be submitted to the Department of Health and Human Services and the Congress later this year.

Agenda: During the morning session, the Task Force will discuss data collection efforts relating to immunosuppressive therapies, networking, organ donation/procurement, research and reimbursement. The afternoon session will be devoted to discussion of issues relating to access to organ transplantation procedures.

The entire meeting is open to the public. Anyone wishing to make a statement may do so between 3:00-4:00 p.m. Please notify Linda D. Sheaffer, Acting Executive Director, if you wish to be scheduled during this session.

Anyone wishing to obtain a roster of members, minutes of meetings, or other relevant information should write to or contact Ms. Linda D. Sheaffer, Acting Executive Director, Office of Organ Procurement and Transplantation, Office of the Administrator, Health Resources and Services Administration, Room 17-60, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857, telephone (301) 443-5911.

Name: National Council on Health Planning and Development.

Date and Time: April 25-26, 1985, 9:00 a.m.

Place: Auditorium, Hubert H. Humphrey Building, 200 Independence Avenue SW.,

Washington, D.C. 20201; the entire meeting is open.

Purpose: The National Council on Health Planning and Development is responsible for advising and making recommendations with respect to (1) the development of national guidelines under section 1501 of Pub. L. 93-641, (2) the implementation and administration of Title XV and XVI of Pub. L. 93-641, and (3) an evaluation of the implications of new medical technology for the organization, delivery and equitable distribution of health care services. In addition, the Council advises and assists the Secretary in the preparation of general regulations to carry out the purposes of section 1122 of the Social Security Act and on policy matters arising out of the implementation of it, including the coordination of activities under that section with those under other parts of the Social Security Act or under other Federal or federally assisted health programs. The Council considers and advises the Secretary on proposals submitted by the Secretary under the provisions of section 1122(d)(2) that health care facilities or health maintenance organizations be reimbursed for expenses related to capital expenditures notwithstanding that under section 1122(d)(1) there would otherwise be exclusion of reimbursement for such expenses.

Agenda: The Council will continue its discussion of the public policy issues of providing health care for those unable to pay for such services. The focus of this meeting, entitled "Uncompensated Care: Identifying Viable Short and Long-Term Strategies," will be on feasible ideas to address the immediate problem as well as on the most efficient and effective alternative strategies over the long-term. Keynote speaker is Senator David Durenberger, Chairman of the Senate Finance Subcommittee on Health.

A public comment period will be held each day. A detailed agenda may be obtained after April 5 by writing or telephoning Mrs. Diane A. McMenamin.

Anyone requiring information regarding the subject Council should contact Ms. Diane McMenamin, Executive Secretary, National Council on Health Planning and Development, Bureau of Health Maintenance Organizations and Resources Development, Room 9A-18, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, Telephone (301) 443-6377.

Agenda items are subject to change as priorities dictate.

Dated: April 1, 1985.

Jackie E. Baum,

*Advisory Committee Management Officer, HRSA.*

[FR Doc. 85-8133 Filed 4-4-85; 8:45 am]

BILLING CODE 4160-15-M